Rigel Pharmaceuticals to Present at Major Investment Conferences This September
Rigel Pharmaceuticals to Shine at Upcoming Investor Conferences
Rigel Pharmaceuticals, Inc., a leading biotechnology firm specializing in treatments for hematologic disorders and cancer, is gearing up for a busy September. The company has confirmed its participation in several high-profile investor conferences, aimed at showcasing its progress and potential in the biopharmaceutical landscape.
Overview of Events
In a recent announcement, Dean Schorno, the Chief Financial Officer of Rigel Pharmaceuticals, revealed that the company will engage in multiple conferences throughout the month. The scheduled events include:
1. Citi's 2026 Biopharma Back to School Conference
Date: Wednesday, September 9, 2026
Location: New York, NY
Rigel will hold one-on-one meetings, allowing investors a unique opportunity to discuss the company's strategy and developments with key executives.
2. Cantor Global Healthcare Conference 2026
Date: Thursday, September 10, 2026
Time: 11:30 AM ET
Location: New York, NY
During this conference, Rigel will not only hold one-on-one meetings but will also present a comprehensive overview of its recent advancements and future plans.
3. H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026
Time: 10:00 AM ET
Location: New York, NY
Similar to previous events, Rigel will participate in one-on-one discussions and present their company overview to a wider audience, reinforcing its commitment to innovation in biopharmaceuticals.
For those interested in accessing the presentations, live webcasts and archived recordings will be made available in the Investor Relations section of Rigel's official website. Attendees are encouraged to log on before the presentations to ensure they have the necessary software.
About Rigel Pharmaceuticals
Founded in 1996 and headquartered in South San Francisco, California, Rigel Pharmaceuticals is devoted to discovering, developing, and commercializing novel therapies that significantly improve the lives of patients afflicted by hematologic disorders and cancer. The company emphasizes innovation and has made considerable strides with its product candidates, aimed at addressing critical unmet medical needs.
Rigel has developed a portfolio of medications and continues to advance its pipeline, with a focus on delivering therapies that are safe and effective, addressing niche markets within oncology and hematology. The company's commitment to research and development positions it prominently within the biotech sector, making events like the upcoming conferences crucial for attracting investment and informing stakeholders about its ongoing projects.
In the words of Dean Schorno, “Our participation in these conferences demonstrates our commitment to transparency and investor engagement. We aim to keep our stakeholders informed about our developments as we continue to work towards bringing hope to patients with serious health conditions.”
As Rigel Pharmaceuticals prepares for these pivotal meetings, it invites interested investors and media representatives to learn more about its impressive journey and the impact of its products. For further details, please visit www.rigel.com.
Investor Relations Contact Information
For any investor inquiries regarding the presentations or events, investors can contact:
- - Rigel Pharmaceuticals, Inc.
Email: [email protected]
Media Contact:
- - David Rosen
- - Argot Partners
- - Phone: 646.461.6387
- - Email: [email protected]
Stay tuned for updates from Rigel Pharmaceuticals as they continue their mission to revolutionize treatment options for patients globally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.